Active
Mainboard

Corona Remedies Ltd

Corona Remedies Ltd IPO Details

Listing Date

15 Dec 2025

Bid Price

₹1008 - ₹1,062

Lot Size

14 Shares

Minimum Investment

₹14,868 / Lot

Issue Size

₹655.37 Cr

Employee Discount

₹54 per share

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

8th Dec

tick

Offer End Date

10th Dec

tick

Allotment Date

11th Dec

tick

Refund Initiation

12th Dec

tick

Demat Transfer

12th Dec

tick

Listing Date

15th Dec

About Corona Remedies Ltd IPO

Incorporated in August 2004, Corona Remedies Limited operates as a pharmaceutical company with activities in the development, manufacturing, and marketing of branded formulations. The company’s product portfolio covers multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, urology, and other multispecialty areas. As of June 30, 2025, the portfolio consisted of 71 brands across these categories, including products in vitamins and minerals, nutrition, gastrointestinal, and respiratory segments. The company engages with healthcare professionals through a marketing and distribution network present across 22 states, supported by 2,671 medical representatives. This network is positioned to facilitate product availability in different regions of the Indian pharmaceutical market.
 

Corona Remedies Limited operates two manufacturing facilities located in Gujarat, with a reported aggregate installed formulation capacity of 1,285.44 million units per annum. Based on available domestic sales data for MAT June 2025, the women’s healthcare segment accounted for 28.56% of sales at ₹4,080.26 million, cardio-diabeto products accounted for 23.38% at ₹3,339.96 million, pain management contributed 11.79% at ₹1,684.38 million, and the urology segment accounted for 4.53% at ₹646.65 million. These figures reflect the contribution of individual therapeutic segments within the company’s product basket. The information provided reflects publicly available disclosures and can be cross-checked with official filings for accuracy.

Corona Remedies Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 72.5% 69%
Public Group 27.5% 31%

Corona Remedies Ltd IPO Reservation

QIB Shares Offered 12,23,203 (19.82%)
NII (HNI) Shares Offered 9,17,403 (14.87%)
Retail Shares Offered 21,40,606 (34.69%)
Anchor Investor Shares Offered 18,34,805 (29.73%)
Total Shares Offered 61,71,102
Total Shares With Anchor Investor 61,71,102

Corona Remedies Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 14 ₹14,868
Retail (Max) 13 182 ₹1,93,284
S HNI (Min) 14 196 ₹2,08,152
S HNI (Max) 67 938 ₹9,96,156
B HNI (MIN) 68 952 ₹10,11,024

Corona Remedies Ltd IPO Anchor Portion Size

Bid Date December 05, 2025
Shares Offered 19,59,116
Anchor Investment Details 208.0581192

Corona Remedies Ltd IPO registrar

Bigshare Services Pvt Ltd
Phone Number +91 22626 38200
Email Id investor@bigshareonline.com
Website www.bigshareonline.com

Corona Remedies Ltd IPO Lead Manager

1. JM Financial Ltd

2. IIFL Capital Services Ltd

3. Kotak Mahindra Capital Co. Ltd

Corona Remedies Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹606.34 Cr ₹480.41 Cr ₹408.52 Cr
Reserves and Surplus ₹545.18 Cr ₹419.25 Cr ₹347.36 Cr
Total Borrowing ₹62.69 Cr ₹134.14 Cr ₹2.33 Cr

Corona Remedies Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid Subscription (Times)
Qualified Institutional Buyers (QIBs) 12,88,732 35,89,39,448 278.5214
Non Institutional Investors (NIIs) 9,66,549 20,18,97,066 208.8845
Retail Individual Investors (RIIs) 22,55,281 6,48,02,038 28.7335
Total 45,71,882 62,65,41,440 137.04

Strength of Corona Remedies Ltd

  • Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
  • Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
  • Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
  • Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
  • Qualified, experienced and entrepreneurial management team supported by marquee investors.

Risks Involved

  • The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
  • Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
  • The company derive a significant majority of its revenue from the company operations within India (constituting 96.34% and 96.33% of the company revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for the company products in India, or if its fail to successfully expand into international markets, the company business, results of operations, financial conditions and cash flows may be adversely affected.
  • A significant portion of the company domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of the company domestic sales for MAT June 2025). Any adverse developments affecting its sales in these regions could has an adverse effect on the company business, results of operations, financial condition and cash flows.
  • 70.10% of Its domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect the company business, results of operations, financial condition and cash flows.
  • Its depend on third-party suppliers to procure the company raw materials and finished goods, with whom the company does not has long term contracts, with the company total purchases aggregating to 19.87% and 27.96% of its total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, the company relies on La Chandra Pharmalab Private Limited, its Associate and Group Company, for the supply of certain active pharmaceutical ingredients in the comapny women's healthcare therapeutic area. its cannot assure you that the company will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.
  • As of June 30, 2025, with a portfolio of 71 brands, its held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If its unable to obtain trademarks for the company products and brands or protect other proprietary information, the company business, results of operations, financial condition and cash flows may be adversely affected.
  • The company required to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company operations. If its fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect the company business, results of operations, financial condition and cash flows.
  • Proceeds from the Offer will not be available to it.
  • As of June 30, 2025, its engaged 22 carrying and forwarding agents for the sale of the company products across the regions in which the company market its products, with the company five largest C&F agents contributing to 43.30% and 44.35% of Its revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of the company C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for the company products or its inability to maintain and increase the number of the company arrangements for the distribution of its products could adversely affect the company business, results of operations, financial conditions and cash flows.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Corona Remedies IPO

  • The Indian domestic formulation segment in Financial Year 2025 reported an estimated market value of around ₹2.3 trillion, representing close to 2% of the global pharmaceutical market size.

  • The sector operates within a manufacturing ecosystem that includes production facilities with advanced technology and a specialised workforce engaged in pharmaceutical development.

  • Consumption within the domestic formulation market recorded a compound annual growth rate (CAGR) of about 9% during Financial Years 2020 to 2025, based on available sector data.

  • Market projections sourced from industry estimates indicate a possible CAGR range of 8–9% for the period leading to Financial Year 2030.

  • The estimated value range for the market by Financial Year 2030 has been placed between ₹3.3 trillion and ₹3.5 trillion in published assessments.

  • These projections reflect demand factors that include higher reported cases of long-duration health conditions, rising awareness levels, and wider access to healthcare services in India.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Corona Remedies IPO.    

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Speciality Medicines Limited IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹117.0 - 124.0
IPO Size
₹29,14,00,000
Powerica Limited IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹375.0 - 395.0
IPO Size
₹11,00,00,00,000
Sai Parenteral's Limited IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹372.0 - 392.0
IPO Size
₹4,08,79,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amir Chand Jagadish Kumar Exports Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
GSP CROP SCIENCE LIMITED IPO
Closing Today
Bidding Period
16th Mar 2026 - 3rd Mar 2026
Price Range
₹304.0 - 320.0
IPO Size
₹4,00,00,00,000
INNOVISION LIMITED IPO
Bidding Period
10th Mar 2026 - 3rd Mar 2026
Price Range
₹494.0 - 519.0
IPO Size
₹3,06,00,00,000
RAAJMARG INFRA INVESTMENT TRUST IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹99.0 - 100.0
IPO Size
₹60,00,00,00,000
APSIS AEROCOM LIMITED IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹104.0 - 110.0
IPO Size
₹36,00,00,000
RAJPUTANA STAINLESS LIMITED IPO
Bidding Period
9th Mar 2026 - 3rd Mar 2026
Price Range
₹116.0 - 122.0
IPO Size
₹2,55,00,00,000
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Bidding Period
6th Mar 2026 - 3rd Mar 2026
Price Range
₹91.0 - 98.0
IPO Size
₹20,00,00,000
ELFIN AGRO INDIA LIMITED IPO
Bidding Period
5th Mar 2026 - 3rd Mar 2026
Price Range
₹47.0 - 47.0
IPO Size
₹25,00,00,000
SEDEMAC MECHATRONICS LIMITED IPO
Bidding Period
4th Mar 2026 - 3rd Mar 2026
Price Range
₹1287.0 - 1352.0
IPO Size
₹10,87,00,00,000
ACETECH ECOMMERCE LIMITED IPO
Bidding Period
27th Feb 2026 - 3rd Mar 2026
Price Range
₹106.0 - 112.0
IPO Size
₹49,00,00,000
STRIDERS IMPEX LIMITED IPO
Bidding Period
26th Feb 2026 - 3rd Mar 2026
Price Range
₹71.0 - 72.0
IPO Size
₹36,00,00,000
OMNITECH ENGINEERING LIMITED IPO
Bidding Period
25th Feb 2026 - 2nd Feb 2026
Price Range
₹216.0 - 227.0
IPO Size
₹5,83,00,00,000
YAAP DIGITAL LIMITED IPO
Bidding Period
25th Feb 2026 - 2nd Feb 2026
Price Range
₹138.0 - 145.0
IPO Size
₹80,11,00,000
PNGS REVA DIAMOND JEWELLERY LIMITED IPO
Bidding Period
24th Feb 2026 - 2nd Feb 2026
Price Range
₹367.0 - 386.0
IPO Size
₹3,80,00,00,000
SHREE RAM TWISTEX LIMITED IPO
Bidding Period
23rd Feb 2026 - 2nd Feb 2026
Price Range
₹95.0 - 104.0
IPO Size
₹1,10,24,00,000
CLEAN MAX ENVIRO ENERGY SOLUTIONS LIMITED IPO
Bidding Period
23rd Feb 2026 - 2nd Feb 2026
Price Range
₹1000.0 - 1053.0
IPO Size
₹31,00,00,00,000
MOBILISE APP LAB LIMITED IPO
Bidding Period
23rd Feb 2026 - 2nd Feb 2026
Price Range
₹75.0 - 80.0
IPO Size
₹20,00,00,000
KIAASA RETAIL LIMITED IPO
Bidding Period
23rd Feb 2026 - 2nd Feb 2026
Price Range
₹121.0 - 127.0
IPO Size
₹70,00,00,000
ACCORD TRANSFORMER AND SWITCHGEAR LIMITED IPO
Bidding Period
23rd Feb 2026 - 2nd Feb 2026
Price Range
₹43.0 - 46.0
IPO Size
₹26,00,00,000
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Bidding Period
20th Feb 2026 - 2nd Feb 2026
Price Range
₹75.0 - 79.0
IPO Size
₹1,65,00,00,000
MANILAM INDUSTRIES INDIA LIMITED IPO
Bidding Period
20th Feb 2026 - 2nd Feb 2026
Price Range
₹65.0 - 69.0
IPO Size
₹40,00,00,000
  • All
  • MainBoard
  • SME
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Issue Prize
98.00
Listing Day Close
104.40(6.12%)
ELFIN AGRO INDIA LIMITED IPO
Issue Prize
47.00
Listing Day Close
47.60(2.13%)
SEDEMAC MECHATRONICS LIMITED IPO
Issue Prize
1352.00
Listing Day Close
1452.10(7.40%)
ACETECH ECOMMERCE LIMITED IPO
Issue Prize
112.00
Listing Day Close
117.60(5.36%)
STRIDERS IMPEX LIMITED IPO
Issue Prize
72.00
Listing Day Close
66.50(-6.94%)
OMNITECH ENGINEERING LIMITED IPO
Issue Prize
227.00
Listing Day Close
205.15(-9.69%)
YAAP DIGITAL LIMITED IPO
Issue Prize
145.00
Listing Day Close
133.35(-8.28%)
PNGS REVA DIAMOND JEWELLERY LIMITED IPO
Issue Prize
386.00
Listing Day Close
413.95(7.25%)
SHREE RAM TWISTEX LIMITED IPO
Issue Prize
104.00
Listing Day Close
73.45(-29.81%)
CLEAN MAX ENVIRO ENERGY SOLUTIONS LIMITED IPO
Issue Prize
1053.00
Listing Day Close
867.90(-17.57%)
MOBILISE APP LAB LIMITED IPO
Issue Prize
80.00
Listing Day Close
67.30(-16.25%)
KIAASA RETAIL LIMITED IPO
Issue Prize
127.00
Listing Day Close
116.85(-7.87%)
ACCORD TRANSFORMER AND SWITCHGEAR LIMITED IPO
Issue Prize
46.00
Listing Day Close
52.50(15.22%)
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Issue Prize
79.00
Listing Day Close
80.48(1.27%)
MANILAM INDUSTRIES INDIA LIMITED IPO
Issue Prize
69.00
Listing Day Close
52.45(-24.64%)
FRACTAL INDUSTRIES LIMITED IPO
Issue Prize
216.00
Listing Day Close
217.55(0.93%)
MARUSHIKA TECHNOLOGY LIMITED IPO
Issue Prize
117.00
Listing Day Close
114.00(-2.56%)
AYE FINANCE LIMITED IPO
Issue Prize
129.00
Listing Day Close
128.90(0.00%)
FRACTAL ANALYTICS LIMITED IPO
Issue Prize
900.00
Listing Day Close
847.40(-5.89%)
BIOPOL CHEMICALS LIMITED IPO
Issue Prize
108.00
Listing Day Close
105.50(-1.85%)

Frequently Asked Questions

What is Corona Remedies Ltd IPO?

Answer Field

Corona Remedies Ltd IPO is a Mainboard IPO of 61,71,102 equity shares of a face value of ₹10 aggregating up to ₹655.37 Crores. The issue is priced at ₹1008 to ₹1062 per share. The minimum order quantity is 14 Shares. The IPO opens on December 08, 2025, and closes on December 10, 2025. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Corona Remedies Ltd IPO will open?

Answer Field

The Corona Remedies Ltd IPO opens on December 08, 2025 and closes on December 10, 2025.

What is the lot size of Corona Remedies Ltd?

Answer Field

Corona Remedies Ltd lot size is 14 shares, and the minimum amount required is ₹14,868.

How to apply for Corona Remedies Ltd IPO?

Answer Field

You can apply in Corona Remedies Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Corona Remedies Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Corona Remedies Ltd IPO will be done on December 11, 2025, and the allotted shares will be credited to your demat account by December 12, 2025.

When is Corona Remedies Ltd IPO listing date?

Answer Field

The Corona Remedies Ltd listing date is December 15, 2025.

Who is the registrar of Corona Remedies Ltd IPO?

Answer Field

The registrar of Corona Remedies Ltd IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

JM Financial Ltd,IIFL Capital Services Ltd,Kotak Mahindra Capital Co. Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Corona Remedies Ltd IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Corona Remedies Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 14 shares and ₹14,868 amount.

How can I approve the UPI mandate request for Corona Remedies Ltd IPO?

Answer Field

To apply for Corona Remedies Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Corona Remedies Ltd?

Answer Field

The price of each Corona Remedies Ltd share will be ranging in between ₹1008 to ₹1062 per share.

What is the cut-off time for the UPI mandate for Corona Remedies Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 10, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|